takeda pharmaceutical co ltd
(4502:Tokyo Stock Exchange)
William W. Chin M.D.
Member of Takeda Global Advisory Board,Takeda Pharmaceutical Company Limited
|Age||Total Calculated Compensation||This person is connected to 76 board members in 5 different organizations across 7 different industries.|
See Board Relationships
Dr. William W. Chin, M.D. serves as an Executive Dean at Research, Bertarelli Professor for Translational Medical Science and Professor of Medicine at Harvard Medical School (HMS). Dr. Chin served as Senior Vice President of Discovery & Clinical Research at Eli Lilly and Company. Dr. Chin served as the Vice President of Discovery Biology Research and Clinical Investigation of Eli Lilly and Company since July 2003. Dr. Chin served as Vice President of gene regulation, ...
12-10, Nihonbashi 2-chomePhone: 81 3 3278 2111
Osaka, -- 103-8668
Fax: 81 3 3278 2000
Board Members Memberships*
Columbia College Chicago
Harvard Medical School
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
|Michel Vounatsos||Chief Executive Officer and Director|
|Brenton L. Saunders J.D.||Chairman, Chief Executive Officer and President|
|Vincent A. Forlenza||Chairman and Chief Executive Officer|
Becton, Dickinson and Company
|Yitzhak Peterburg M.D., Dr.P.H., MSc||Interim Chief Executive Officer, Interim President and Director|
Teva Pharmaceutical Industries Limited
|Lars Fruergaard Jørgensen||Chief Executive Officer and President|
Novo Nordisk A/S
|kr8.7M||Compensation as of Fiscal Year 2016.|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.